Immunohistochemical and molecular subtypes of breast cancer in Nigeria

Breast Cancer Research and Treatment

Volumn 110, Issue 1, 2008, Pages 183-188

  Adebamowo, Clement A ^a   Famooto, Ayotunde ^a   Ogundiran, Temidayo O ^a   Aniagwu, Toyin ^a   Nkwodimmah, Chibuzor ^a   Akang, Effiong E ^b  

^a UNIVERSITY OF IBADAN   (Nigeria)

^b UNIVERSITY OF IBADAN   (Nigeria)

Author keywords

Breast cancer; ER; HER2 neu; Molecular subtypes; Nigeria; PR

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER STAGING; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NIGERIA; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 44849129524     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-007-9694-5     Document Type: Article

References (32)

1. Parkin DM, Ferlay J, Hamdi-Cherif M et al (2003) Cancer in Africa: epidemiology and prevention. IARC Press, Lyon
2. American Cancer Society (2007) Cancer facts & figures 2007. American Cancer Society, Atlanta
3. Ihekwaba FN (1992) Breast cancer in Nigerian women. Br J Surg 79:771-775
4. Adebamowo CA, Adekunle OO (1999) Case-controlled study of the epidemiological risk factors for breast cancer in Nigeria. Br J Surg 86:665-668
5. Anyanwu SN (2000) Breast cancer in eastern Nigeria: a ten year review. West Afr J Med 19:120-125
6. Hassan I, Onukak EE, Mabogunje OA (1992) Breast cancer in Zaria, Nigeria. J R Coll Surg Edinb 37:159-161
7. Otu AA, Ekanem IO, Khalil MI et al (1989) Characterization of breast cancer subgroups in an African population. Br J Surg 76:182-184
8. Chiedozi LC (1985) Breast cancer in Nigeria. Cancer 55:653-657
9. Elmore JG, Moceri VM, Carter D, Larson EB (1998) Breast carcinoma tumor characteristics in black and white women. Cancer 83:2509-2515
10. Middleton LP, Chen V, Perkins GH et al (2003) Histopathology of breast cancer among African-American women. Cancer 97:253-257
11. Mbonde MP, Amir H, Mbembati NA et al (1998) Characterisation of benign lesions and carcinomas of the female breast in a sub-Saharan African population. Pathol Res Pract 194:623-629
12. Jones BA, Kasi SV, Curnen MG et al (1997) Severe obesity as an explanatory factor for the black/white difference in stage at diagnosis of breast cancer. Am J Epidemiol 146:394-404
13. Miller BA, Hankey BF, Thomas TL (2002) Impact of sociodemographic factors, hormone receptor status, and tumor grade on ethnic differences in tumor stage and size for breast cancer in US women. Am J Epidemiol 155:534-545
14. Gukas ID, Jennings BA, Mandong BM et al (2005) Clinicopathological features and molecular markers of breast cancer in Jos, Nigeria. West Afr J Med 24:209-213
15. Ikpatt OF, Kuopio T, Ndoma-Egba R, Collan Y (2002) Breast cancer in Nigeria and Finland: epidemiological, clinical and histological comparison. Anticancer Res 22:3005-3012
16. Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes and survival in the Carolina Breast Cancer Study. JAMA 295:2492-2502
17. Burstein HJ (2005) The distinctive nature of Her2 positive breast cancers. N Engl J Med 353:1652-1654
18. Murray E (2005) Breast cancer clinic at Groote Schuur Hospital. In: AORTIC Newsletter, Edition 2005, pp 10-11
19. Adebamowo CA, Ogundiran TO, Akang EE, Adams-Campbell LL (2003) ER/PR Status of Nigerian Breast Cancer Patients. In: American Association for Cancer Research Annual Meeting, Edition. AACR, Washington, DC, p 103301
20. Bertheau P, Cazala-Hatern D, Meignin V et al (1998) Variability of stored immunohistochemical reactivity on stored paraffin slides. J Clin Pathol 51:370-374
21. Olapade-Olaopa EO, Mackay HE (1998) Variability of immunohistochemical reactivity on stored paraffin slides. J Clin Pathol 51:943
22. Goldstein NS, Ferkowicz M, Odish E et al (2003) Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am J Clin Pathol 120:86-92
23. von Wasielewski R, Mengel M, Nolte M, Werner M (1998) Influence of fixation, antibody clones, and signal amplification on steroid receptor analysis. Breast J 4:22-40
24. Ogbimi RI, Adebamowo CA (2006) Questionnaire survey of working relationships between nurses and doctors in University Teaching Hospitals in Southern Nigeria. BMC Nursing 5:2
25. Cockburn R, Newton PN, Agyarko EK et al (2005) The global threat of counterfeit drugs: why industry and governments must communicate the dangers. PLoS Med 2:e100
26. Mann GB, Fahey VD, Feleppa F, Buchanan MR (2005) Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer. J Clin Oncol 23:5148-5154
27. Nichols HB, Trentham-Dietz A, Love RR et al (2005) Difference in breast cancer risk factors by tumor marker subtypes among premenopausal Vietnamese and Chinese women. Cancer Epidemiol Biomarkers Prev 14:41-47
28. Schechter AL, Stern DF, Vaidyanathan L et al (1984) The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 312:513-516
29. Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182
30. Clark GM, McGuire WL (1991) Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 51:944-948
31. Jones BA, Kasl SV, Howe CL et al (2004) African American/white differences in breast carcinoma: p53 alterations and other tumor characteristics. Cancer 101:1293-1301
32. Sørlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869-10874